Management of pediatric hypertrophic cardiomyopathy

Current Opinion in Cardiology

Volumn 20, Issue 2, 2005, Pages 80-83

  Yetman, Anji T ^a   McCrindle, Brian W ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Hypertrophic cardiomyopathy; Prognosis; Sudden death

Indexed keywords

ALCOHOL; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DISOPYRAMIDE; VERAPAMIL;

ADOLESCENT; CHILD; CHILDHOOD DISEASE; DEFIBRILLATOR; DIAGNOSTIC IMAGING; DIASTOLE; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG INDICATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EVALUATION; EXERCISE TEST; GENETIC ANALYSIS; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE SEPTUM; HOLTER MONITORING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ANALYSIS; MUSCLE RESECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PHENOTYPE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SAFETY; SUDDEN DEATH;

CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; CHILD; DEATH, SUDDEN, CARDIAC; HUMANS; PEDIATRICS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 15344341336     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000153452.45341.36     Document Type: Review

References (24)

1. Nishimura RA, Holmes DR. Hypertrophic obstructive cardiomyopathy. N Engl J Med 2004; 350:1320-1327.
2. Frenneux MP. Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy. Heart 2004; 90:570-575. This article outlines the potential mechanisms of sudden death in HCM and provides a review of both clinically useful established risk factors as well as clinical markers of unproven clinical utility.
3. Chung MW, Tsoutsman T, Semsarian C. Hypertrophic cardiomyopathy: from gene defect to clinical disease. Cell Res 2003; 13:9-20. This report provides a comprehensive outline of the molecular pathogenesis of HCM.
4. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004; 363: 1881-1891.
5. Woo A, Rakowski H, Liew JC, et al. Mutations of the beta myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis. Heart 2003; 89:11 79-1185. This is a cohort study of HCM patients with the beta MHC genetic defect and their family members, noting heterogeneity of disease expression based on the type of genetic mutation.
6. Jongbloed RJ, Marcelis CL, Doevendans PA, et al. Variable clinical manifestation of a novel missense mutation in the alpha-tropomyosin gene in familial hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41:994-996.
7. Maron BJ, McKenna WJ. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2003; 42:1687-1713. This consensus document provides a comprehensive clinical treatment algorithm for the treatment of children with HCM, and addresses topics of controversy including the role of pacemaker management, implantable cardiac defibrillators, and alcohol septal ablation.
8. Tsybouleva N, Zhang L, Chen S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defects and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 2004; 109:1284-1291. This report explores the clinical question of genetic heterogeneity with an emphasis on aldosterone as a potential modulator in disease expression.
9. Charron P, Heron D, Gargiulo M, et al. Prenatal molecular diagnosis in hypertrophic cardiomyopathy: report of the first case. Prenat Diagn 2004; 24:701.
10. McMahon CJ, Nagueh SF, Pignatelli RH, et al. Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. Circulation 2004; 109:1756-1773. This is the first study to demonstrate abnormalities on tissue Doppler imaging in children with HCM, and to relate these abnormalities with other clinical variables.
11. Konno T, Shimizu M, Ino H, et al. Diagnostic value of abnormal Q waves for identification of preclinical carriers of hypertrophic cardiomyopathy based on a molecular genetic diagnosis. Eur Heart J 2004; 25:246-251.
12. Monserrat L, Elliot PM, Gimeno JR, et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003; 42:873-879, This report describes the identification of a new marker of sudden death risk for young patients with HCM.
13. Drinko JK, Nash PJ, Lever HM, Asher CR. Safety of stress testing in patients with hypertrophic cardiomyopathy. Am J Cardiol 2004; 93:1443-1444. Many physicians fail to perform cardiopulmonary stress tests on children with HCM due to fear of adverse events. This paper demonstrates the safety of stress testing in a large number of patients with HCM.
14. Amano Y, Takayama M, Takahama K, Kumazaki T. Delayed hyper-enhancement of myocardium in hypertrophic cardiomyopathy with asymmetrical septal hypertrophy. Comparison with global and regional cardiac MR image appearances. J Magn Reson Imaging 2004; 20:595.
15. Sorajja P, Ommen SR, Nishimura RA, et al. Myocardial bridging in adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 99:889-894.
16. Downar J, Williams WG, McDonald C, et al. Outcomes after unroofing of a myocardial bridge of the left anterior descending coronary artery in children with hypertrophic cardiomyopathy. Pediatric Cardiol 2004 This is a follow-up paper of children with HCM and surgical myectomy of myocardial bridges of epicardial coronary arteries. Myocardial bridging has been suggested to be a cause of ischemia and an important risk factor for sudden death in children with HCM, and these authors provide evidence in a small case series of resolution of symptoms with unroofing.
17. Cecchi F, Olivotto I, Gistri R, et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003; 349:1027-1035.
18. Maron BJ. AHA Scientific Statement. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109:2807-2816. This comprehensive panel statement summarizes the current recommendations for physical activity in children with HCM, long QT syndrome, Brugada syndrome, arrhythmogenic right ventricular dysplasia, and Marfan syndrome.
19. Minikata K, Dearani JA, Nishimura RA, et al. Extended septal myectomy for hypertrophic cardiomyopathy with anomalous mitral papillary muscle and chordae. J Thorac Cardiovasc Surg 2004; 127:481-489. This report deals with the difficult topic of how to surgically address left ventricular outflow tract obstruction when the mitral valve apparatus is an integral part of the obstruction, and provides an alternative treatment strategy to mitral valve replacement.
20. Alexander MF, Cecchin F, Waish EP, et al. Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics. J Cardiovasc Electrophysiol 2004; 15:77-78. This retrospective review documents a high incidence of complications in children who have had an implantable cardiac defibrillator.
21. Begley DA, Mohiddin SA, Tripodi D, et al. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 2003; 26:1887-1896. This report outlines survival rates and therapeutic implantable cardiac defibrillator intervention-free rates for patients receiving a defibriilator for primary prevention or secondary prevention, and notes a higher rate of therapeutic implantable cardiac defibrillator intervention in patients aged less than 21 years.
22. Luedemann M, Hund K, Stertmann W, et al. Implantable cardioverter defibrillator in a child using a single subcutaneous array lead and an abdominal active can. Pacing Clin Electrophysiol 2004; 27:117-119. This report describes a novel alternative to epicardial patches for implantable cardiac defibrillator placement in a small child.
23. Kuhn H, Seggeweiss H, Gietzen FH, et al. Catheter-based therapy for hypertrophic cardiomyopathy. First in-hospital outcome analysis of German TASH registry. Z Kardiol 2004; 93:23-31.
24. Aroney CN, Goh TH, Hourigan LA, Dyer W. Ventricular septal rupture following nonsurgical septal reduction for hypertrophic cardiomyopathy: treatment with percutaneous closure. Catheter Cardiovasc Interv 2004; 61: 411-414.